Compare Kroger Co (KR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Regeneron Pharmaceuticals Inc — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.1× Kroger Co's market cap, and Kroger Co pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| KR | REGN | |
|---|---|---|
Market Cap | $36.27B | $76.14B |
Volume | 8,301,523 | 500,239 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $852.03 |
52-Week Low | $55.53 | $557.73 |
Typical Hold Time | 108 Days | 107 Days |
Enterprise Value | $57.69B | $70.85B |
Dividend Yield | 2.54% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.41, up 3.65% with a bullish technical outlook. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, though net margin remains thin at 0.73%. Recent earnings beat expectations in Q2 2026, and the company maintains consistent dividends. Analysts are moderately bullish with a $70.62 consensus target, citing digital growth and operational improvements as key drivers.
KR offers value with low P/S (0.26) and stable cash flow generation, but faces risks from competitive pressures and integration challenges from acquisitions. The stock presents opportunity for investors seeking defensive exposure with dividend income, though margin compression and economic sensitivity warrant caution.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
